Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update,

Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL. PBCAR0191 Phase 1/2a Trial is …, Dosed First Patient in Phase 1/2a Clinical Study of PBCAR20A in Relapsed/Refractory NHL, CLL, and SLL. PBCAR0191 Phase 1/2a Trial is …, Read More

Scroll to Top